

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2016-2017) - Novartis : Hypertension (2016-2017) - Boehringer-Ingelheim : Oral anticoagulation (2016-2017) - Bayer Healthcare : Oral anticoagulation (2016-2017) - Pfizer/BMS alliance : Oral anticoagulation (2016-2017)
Agabiti-Rosei Enrico	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Doc Generici : Cardiometabolic (2016-2017) - Bruno Farmaceutici : Cardiometabolic (2016-2017) - Servier : Cardiovascular (2016-2017) - Malesci : Cardiovascular (2016-2017) - Recordati International : Cardiovascular (2016-2017) - Guidotti : Cardiovascular (2016-2017) - Stroder : Cardiovascular (2016-2017) - MENARINI INTERNATIONAL : cardiovascular (2016-2017) - Novartis : cardiovascular (2017)
Azizi Michel	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - CVRx : Baroreceptor stimulation (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Azizi Michel	<ul style="list-style-type: none"> - Actelion : hypertension (2016-2017) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - Quantum Genomics : Hypertension (2016) - Novartis : Hypertension (2016-2017) - Recor : renal denervation (2016-2017)
Burnier Michel	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer- Ingelheim : Diabetes (2016) - Servier : Hypertensio (2016) - Sankyo : Hypertension (2016) - Menarini : Hypertension (2016-2017) - Boehringer-Ingelheim : Diabetes (2017) - Amgen : dialysis (2017) - Daichi-Sankyo : Hypertension (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : Diabetic nephropathy (2016) - Pfizer : Dyslipidemia (2016) - Amgen Inc : Dyslipidemia (2016) - Amgen Inc : Hyperparathyroidism (2016) - Medtronic : Resistant hypertension (2016) - Actelion : ENdothelin antagonists (2016-2017) - Boehringer-Ingelheim : SGLT2 inhibitors (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Clement Denis	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - European Society of Cardiology : editor e-journal (2016-2017)
Coca Antonio	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016) - Merck Serono : Bisoprolol-Amlodipine (2016-2017) - Menarini : Nebivolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017) - Ferrer Internacional : Torasemide; CardiIncode microchips; Polypill (2016-2017)
de Simone Giovanni	1- Financial Declaration D - Research funding (departmental or institutional) from healthcare industry. - Italian Ministry of University : Hypertension - Coronary Heart Disease (2016-2017)
Desormais Ileana	Nothing to be declared (2016-2017)
Dominiczak Anna F	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : Cardiovascular (2016-2017) - Menarini : Cardiovascular (2016-2017) 2- Other Positions of Influence 2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. - Non-executive Director, NHS Greater Glasgow and Clyde Health Board, this is a non-executive position with a role in a high level strategy but not with any direct purchasing or other executive decisions. (2016-2017) 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Trustee of the British Heart Foundation (also a non-executive position). (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Kahan Thomas	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Amgen : Cardiovascular risk assessment (2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Recor Medical : Renal enervation (2016)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Pfizer : Lipid lowering therapy (2016-2017) - Medtronic : Renal denervation (2016-2017) - Amgen Inc : Lipid lowering therapy (2017) - Regeneration Pharmaceuticals : Lipid lowering therapy (2017) - Recor : Renal denervation (2017)</p>
Kerins Mary	Nothing to be declared (2016-2017)
Kjeldsen Sverre Erik	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : Drug producer (2016) - Takeda Pharmaceuticals : Drug producer (2016) - Merck Sharp & Dohme : Drug producer (2016) - ABDiiBRAHiM : Drug producer (2016) - Sanofi Aventis : Antihypertensive drugs (2017) - Bayer Healthcare : Antihypertensive drugs (2017) - Takeda Pharmaceuticals : Antihypertensive drugs (2017)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Kjeldsen Sverre Erik	<ul style="list-style-type: none"> - Merck Sharp & Dohme : Antihypertensive drugs (2017) C - Receipt of royalties for intellectual property. <ul style="list-style-type: none"> - Gyldendal textbook publisher : Internal medicine (2016) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - Norwegian Council for Cardiovascular Diseases : Clinical reasearch (2016) - South East Norway Health Authority : Clinical Resarch (2016)
Kreutz Reinhold	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular (2016) - Daiichi Sankyo : Cardiovascular, anticoagulation (2016) - Bayer AG : Cardiovascular, anticoagulation (2016) - Servier : Cardiovascular, hypertension (2016) - Berlin Chemie AG : Hypertension (2016) - Daiichi Sankyo : Anticoagulation (2017) - Bayer AG : Anticoagulation (2017) - Servier : Hypertension (2017) - Berlin Menarini : Hypertension (2017) - Astra Zeneca : Pharmacotherapy (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : Anticoagulation (2016-2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Member of the Scientific Council of the European Society of Hypertension (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Laurent Stephane	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : hypertension (2016-2017)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : hypertension (2016-2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Axelife : Cardiology (2016-2017)</p>
Lip Gregory Y H	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - BMS/Pfizer : Anticoagulation (2016) - Boehringer Ingelheim : Anticoagulation (2016) - Daiichi-Sankyo : Daiichi-Sankyo (2016) - Medtronic : AF screening (2016-2017) - Bayer/Janssen : Anticoagulation (2016-2017) - Daiichi-Sankyo : Anticoagulation (2017) - Verseon : Anticoagulation development (2017) - Boehringer Ingelheim : Anticoagulation; Registries; Steering Committees (2017) - Pfizer : Anticoagulation; Registries (2017) - BMS : Antithrombotic therapy (2017) - Novartis : Antithrombotic therapy development (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - BMS/Pfizer : AF Registries [unrestricted educational grant] (2016-2017)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lip Gregory Y H	- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016-2017)
Mahfoud Felix	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Interventional cardiology (2016) - Medtronic : Interventional cardiology (2016-2017) - Recor : Interventional Cardiology (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : Study fees (2016) - St Jude Medical : Study fees (2016) - Medtronic : Interventional Cardiology (2017) - Recor : Interventional Cardiology (2017)
Mancia Giuseppe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antihypertensive Treatment (2016-2017) - Boehringer-Ingelheim : Antihypertensive Treatment (2016-2017) - Daiichi Sankyo : Antihypertensive Treatment (2016-2017) - Novartis : Antihypertensive Treatment (2016-2017) - Menarini : Antihypertensive Treatment (2016-2017) - Medtronic Foundation : Antihypertensive Treatment (2016-2017) - Servier : Antihypertensive Treatment (2017) - Recordati International : Antihypertensive Treatment (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Mancia Giuseppe	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Antihypertensive Treatment (2016) - Sanofi Aventis : Antihypertensive Treatment (2016) - Recordati International : Antihypertensive Treatment (2016) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor of the Journal of Hypertension (2017)
McManus Richard	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - OMRON Healthcare : BP monitors for research (2014&15) (2016-2017) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - I hold shares in a primary care medical practice in Birmingham, UK (2016-2017) <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - I am a partner in a general practice in Oxford. (2016-2017) <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - I chair the British Hypertension Society BP monitoring Working Party (2016-2017)
Narkiewicz Krzysztof	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Gilead : Pharmacotherapy (2016) - Adamed : Cardiovascular pharmacotherapy (2016-2017) - Polpharma : Cardiovascular pharmacotherapy (2016-2017) - Servier : Cardiovascular pharmacotherapy (2016-2017) - Berlin Menarini : Cardiovascular pharmacotherapy (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Narkiewicz Krzysztof	<ul style="list-style-type: none"> - Krka Pharma : Cardiovascular pharmacotherapy (2016-2017) - Gedeon Richter : Cardiovascular pharmacotherapy (2016-2017) - Mylan : Cardiovascular pharmacotherapy (2016-2017) - Valeant : Cardiovascular pharmacotherapy (2016-2017) - Resmed : Respiratory medicine (2016-2017) - Actelion : Cardiovascular pharmacotherapy (2017) - Egis Pharma : Cardiovascular pharmacotherapy (2017) - Sandoz : Cardiovascular pharmacotherapy (2017) - Merck Polska : Cardiovascular pharmacotherapy (2017) - Medtronic : Renal denervation (2017)
Redon Josep	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2016) - Menarini : Hypertension (2016) - MSD : Hypertension (2016) - Boehringer-Ingelheim : Diabetes (2016-2017) - MENARINI INTERNATIONAL : CARDIOVASCULAR (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Hypertension (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ruilope Luis Miguel	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sanofi Aventis : alirocumab (2016) - Janssen-Cilag : Canagliflozin (2016) - Astra Zeneca : Dapagliflozin (2016) - Novartis : Entresto and vavaran combinations (2016) - Medtronic : European Registry of RDN (2016) - Amgen : Evolocumab (2016) - Menarini : olesartan and combinations (2016) - Daiichi Sankyo : Olmesartan & combinations (2016) - Merck Sharp & Dohme : Olmesartan and combinations (2016) - Servier : perindopril new combinations (2016) - Bayer AG : Finerenone (2016-2017) - Vifor International : patiomer (2016-2017) - Daiichi Sankyo : Arterial Hypertension (2017) - Medtronic : Renal denervation (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes, nocturnal BP and dapagliflozina (2016)
Ruschitzka Frank	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Drug (2016) - St. Jude Medical : Medical devices (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ruschitzka Frank	<ul style="list-style-type: none"> - Heartware : Ventricular assist devices (2016) - Amgen : Drug (2016-2017) - Pfizer : Drug (2016-2017) - BMS : Drug (2016-2017) - Servier : Drugs (2016-2017) - Sanofi Aventis : Drugs (2016-2017) - Zoll Medical : LifeVest (2016-2017) - Fresenius Nutrition : Steering Committee Meetings of Clinical Trials (2016-2017) - Vifor International : Steering Committee Meetings of Clinical Trials (2016-2017) - Cardioentis : TRUE-AHF Steering Committee (2016-2017) - Bayer Healthcare : Drug (2017) - Astra Zeneca : Drugs (2017) - Novartis : Drugs (2017) - Roche Pharma : Drugs (2017) - Abbott : Medical Devices (2017) - Boehringer-Ingelheim : Satellite Symposium (2017) - Heartware : Ventricular assist device (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2016) - St Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2016) - Novartis : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ruschitzka Frank	<ul style="list-style-type: none"> - Bayer Healthcare : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2017) - St. Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Mars : Flavanol-like cocoa products (2016-2017) - St. Jude Medical : Medical Devices (2017) - Novartis : VASCEND (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Cardiomaxx Consulting GmbH account for managing reimbursements and expenses (2016-2017)
Schmieder Roland	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Nephrology and Hypertension (2016) - Kona Medical : Nephrology and Hypertension (2016) - Medtronic : Nephrology and Hypertension (2016-2017) - Novartis : Nephrology and Hypertension (2016-2017) - Servier : Nephrology and Hypertension (2016-2017) - Berlin Chemie AG : Nephrology and Hypertension (2016-2017) - Recor : Nephrology and Hypertension (2016-2017) - Bayer Vital : Nephrology and Hypertension (2016-2017) - Astra Zeneca : Nephrology and Hypertension (2017) - Daiichi Sankyo : Nephrology and Hypertension (2017) - Novo-Nordisk : Nephrology and Hypertension (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Schmieder Roland	<ul style="list-style-type: none"> - Rox Medical : Nephrology and Hypertension (2017) - Vasopharm : Nephrology and Hypertension (2017) - Ablative Solution : Nephrology and Hypertension (2017) - Hexal : Nephrology and Hypertension (2017) - Boehringer-Ingelheim : Nephrology and Hypertension, Diabetes mellitus (2017) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - BMBF - German Ministry of Research and Education : Nephrology and Hypertension (2016) - Rox Medical : Nephrology and Hypertension (2016) - Recordati International : Nephrology and Hypertension (2016) - Kona : Nephrology and Hypertension (2016) - Vascular Dynamics : Nephrology and Hypertension (2016) - Vasopharm : Nephrology and Hypertension (2016) - Ablative Solution : Nephrology and Hypertension (2016) - Medtronic : Nephrology and Hypertension (2016-2017) - Novartis : Nephrology and Hypertension (2016-2017) - Recor : Nephrology and Hypertension (2016-2017) - Boehringer Ingelheim : Nephrology and Hypertension (2016-2017) - Ablative Solutions : Nephrology and Hypertension (2017) - Roxmedical : Nephrology and Hypertension (2017)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<ul style="list-style-type: none"> - Novartis : Arterial Hypertension, Heart Failure (2016-2017) - Merck Sharp & Dohme : Atherosclerosis (2016-2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017) - Pfizer : General Cardiology (2016-2017)
Spiering Wilko	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Janssen-Cilag. : Canagliflozin. (2016) - Vascular Dynamics. : Endovascular baroreflex amplification device. (2016) - Vascular Dynamics : Endovascular barreflex amplification device. (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Vascular Dynamics. : Endovascular baroreflex amplification device. (2016) - Vascular Dynamics : Endovascular barreflex amplification device. (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - President Dutch Hypertension Society. (2016-2017)
Tsioufis Costas	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiology (2016-2017) - Bayer : Cardiology (2016-2017) - Boehringer-Ingelheim : Cardiology (2016-2017) - Medtronic : Cardiology (2016-2017) - Novartis : Cardiology (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Tsioufis Costas	<ul style="list-style-type: none"> - Pfizer : Cardiology (2016-2017) - Servier : Cardiology (2016-2017) - St Jude Medical : Cardiology (2016-2017) - Sanofi Aventis : Cardiology (2016-2017) - Chiesi Pharma : Cardiology (2016-2017) - Recordati International : Cardiology (2016-2017) - Vianex : Cardiology (2016-2017) - Winmedica : Cardiology (2016-2017) - ELPEN : Cardiology (2016-2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Medtronic : Cardiology (2016-2017) - St Jude Medical : Cardiology (2016-2017)
Williams Bryan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Hypertension (2016-2017) - Daiichi Sankyo : Hypertension (2016-2017) - Novartis : Hypertension (2016-2017) - Servier : Hypertension (2016-2017) - Vascular Dynamics Inc, USA : Hypertension - device based therapy (2016-2017) - Pfizer : Hypertension and cardiovascular risk management (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Williams Bryan	2- Other Positions of Influence 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Trustee of BP UK - a patient's association (2016-2017)
Zanchetti Alberto	Declaration not submitted (2017) 1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Menarini : Speaker Fees (2016) - Recordati International : Speaker Fees (2016)

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Agewall Stefan	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Antiplatelet treatment (2017)
Aksnes Tonje	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Honoraria for lecture (2017)
Andersen Karl	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Novartis : ACS (2017)
Aydogdu Sinan	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Amgen : Antihyperlipidemics (2017) - Astra Zeneca : Antiplatelets (2017) - Daiichi Sankyo : Antiplatelets (2017) - Bayer : Oral anticoagulant agents (2017) - Boehringer-Ingelheim : oral anticoagulants (2017) - Pfizer : oral anticoagulants (2017)
Bajraktari Gani	Nothing to be declared (2017)

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Baranova Elena	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : Aspirin (2017) - Bayer : aspirin (2017) - Boehringer-Ingelheim : Dabigatran etexilate, empagliflozine (2017) - Berlin Menarini : Ranolazine, Zopenopril, Lercanidipine (2017) - Servier : Triplixam, Preterax, Noliprel (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : ARNI (2017) - Sanofi Aventis : PCSK-9 (2017)
Barbato Emanuele	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Education courses on rotational atherectomy (2017) - Abbott Vascular : Educational courses on FFR (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Unrestricted grant for an investigator-driven study (2017)
Benkhedda Salim	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Report HF study (2017)
Bertomeu Martinez Vicente	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulation (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bertomeu Martinez Vicente	<ul style="list-style-type: none"> - Pfizer : Anticoagulation (2017) - Menarini : Coronary Disease (2017)
Bochud Murielle	Nothing to be declared (2017)
Borghi Claudio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2017) - Servier : Hypertension, dislipydemia, heart failure (2017) - Menarini : Hyperuricemia and Gout (2017) - Grunenthal : Hyperuricemia and Gout (2017)
Boutouyrie Pierre	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - ACER Therapeutics : celiprolol (2017)
Brady Adrian Jb	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : AF anticoagulation (2017) - Bayer AG : anticoagulation (2017) - Astra Zeneca : Antiplatelet therapy (2017) - Sanofi Aventis : Lipid lowering (2017) - Amgen Inc : Lipid lowering (2017) - MSD : Lipid lowering (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Brguljan Jana	Nothing to be declared (2017)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Apixaban (2017) - Bristol Myers Squibb : Apixaban (2017) - Bayer : Aspirin, rivaroxaban (2017) - MEDSCAPE-the heart.org : Inespecific (2017) - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) - Astra Zeneca : Ticagrelor (2017) - Ferrer Internacional : Trinomia (polypill) (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial (2017) - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - VP elect. Spanish Society of Cardiology FAHA (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Burkard Thilo	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : Diabetes mellitus (2017) - Sanofi Aventis : Dyslipidemia (2017) - Servier : Hypertension, Dyslipidemia (2017) D - Research funding (departmental or institutional) from healthcare industry. - Novartis : Study site of a Novartis - initiated hypertension trial (2017)
Caiani Enrico Gianluca	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic : implanted defibrillators (2017)
Caraus Alexandru	2- Other Positions of Influence 2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. - Deputy Director Institute of Cardiology (2017)
Carlberg Bo	Nothing to be declared (2017)
Carvalho Rodrigues Manuel	Nothing to be declared (2017)
Cassar Demarco Daniela	Nothing to be declared (2017)
Chapman Neil	Nothing to be declared (2017)
Chazova Irina	Nothing to be declared (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Cifkova Renata	Nothing to be declared (2017)
Cleland John	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Philips : Cardiac Imaging (2017) - Amgen : Heart Failure (2017) - Medtronic : Heart Failure (2017) - Novartis : Heart Failure (2017) - Servier : Heart Failure (2017) - Johnson & Johnson : Heart Failure (2017) - Bayer Healthcare : Heart Failure (2017) - Vifor International : Heart Failure (2017) - Roche Diagnostics : Heart Failure (2017) - Zoll Medical : Heart Failure (2017) - Sensible Medical : Heart Failure (2017) - Stealthpeptides : Heart Failure (2017) - Corvedia : Heart Failure (2017) - Actelion : Pulmonary Hypertension (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer Healthcare : CV Disease (2017) - Amgen : Heart Failure (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Cleland John	<ul style="list-style-type: none"> - Novartis : Heart failure (2017) - Philips : Heart Failure (2017) D - Research funding (departmental or institutional) from healthcare industry. - Bayer Healthcare : CV Disease (2017) - Amgen : Heart Failure (2017) - Novartis : Heart Failure (2017) - Philips : Heart Failure (2017) - Alere : Heart failure (2017) - Roche Diagnostics : Heart Failure (2017) - Thermofisher : Heart Failure (2017) - Stealth Biopharmaceuticals : heart failure (2017)
Coca Antonio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Merck Serono : Bisoprolol-Amlodipine (2017) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2017) - Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2017)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
De Backer Guy	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : speaker fee, 2017 (2017)
de Backer Tine Leonie Marie	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation, hypertension (2017) - Servier : Hypertension (2017) - Daiichi Sankyo : Hypertension, anticoagulation (2017)
De Leeuw Peter W	<p>Nothing to be declared (2017)</p>
De Pauw Michel	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2017) - Actelion : Pulmonary Hypertension (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017)
Dendale Paul	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : lipids (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : CV (2017) - Astra Zeneca : cv drugs (2017) - Bayer : cv medication (2017) - Boehringer-Ingelheim : cv medication (2017) - Daiichi Sankyo : cv medication (2017) - Novartis : cv medication (2017) - Vifor International : cv medication (2017) - Therabel : cv medication (2017) - Philips : echocardio (2017) - GE Healthcare : echocardio (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Dendale Paul	<ul style="list-style-type: none"> - Medtronic : pm (2017) - St Jude Medical : pm (2017) - Biotronik : pm (2017) - Boston Scientific : stents (2017)
Denolle Thierry	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : cardiology (2017) - Servier : cardiology (2017) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Biotrial CRO, Rennes, France (part time for consultancy) (2017)
Diener Hans-Christoph	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Portola Pharmaceuticals : Andexanet alfa (2017) - Allergan : Spasticity (2017) - Abbott : Stroke (2017) - Astra Zeneca : Stroke (2017) - Boehringer-Ingelheim : Stroke (2017) - Covidien : Stroke (2017) - Daiichi Sankyo : Stroke (2017) - Medtronic : Stroke (2017) - Novartis : Stroke (2017)

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Diener Hans-Christoph	<ul style="list-style-type: none"> - Pfizer : Stroke (2017) - Servier : Stroke (2017) - Sanofi Aventis : Stroke (2017) - GlaxoSmithKline : Stroke (2017) - Bayer Healthcare : Stroke (2017) - Merck Sharp & Dohme : Stroke (2017) - Ev3 : Stroke (2017) - CoAxia : Stroke (2017) - D-Pharm : Stroke (2017) - Neurobiological technologies : Stroke (2017) - Paion : Stroke (2017) - Thrombogenics : Stroke (2017) - Bristol Myers Squibb : Stroke Prevention (2017) - St. Jude : Stroke, LAA occlusion (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - German Stroke Foundation : Stroke (2017) - German Research Foundation : Stroke (2017) - German Ministry of Education and Research (BMBF) : Stroke (2017) - Hein-Nixdorf Foundation : Stroke (2017) - NIH : Stroke (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Dizdarevic-Hudic Larisa	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer : Ertugliflozin (subinvestigator in study) (2017)
Djordjevic-Dikic Ana	Nothing to be declared (2017)
Dorobantu Maria	Nothing to be declared (2017)
Erdine Serap	Nothing to be declared (2017)
Fagard Robert	Nothing to be declared (2017)
Farsang Csaba	Nothing to be declared (2017)
Ferrini Marc	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bristol Myers Squibb : Apixaban (2017) - Novartis : LCZ (2017) - Bayer : Rivaroxaban, Aspirin (2017) - Astra Zeneca : Ticagrelor (2017)
Fitzsimons Donna	Nothing to be declared (2017)

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Foscoli Marina	Nothing to be declared (2017)
Fras Zlatko	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation therapy (2017) - Astra Zeneca : antiplatelet therapy (2017) - Boehringer-Ingelheim : cardiometabolism (2017) - Amgen : lipid treatment (2017) - Sanofi Aventis : lipid treatment (2017) - Krka Pharma : lipids (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Sanofi Aventis : lipidology (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Sanofi Aventis : lipidology (2017)
Gaemperli Oliver	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - GE Healthcare : Imaging (2017)
Gerds Eva	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular (2017)

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Gottsater Anders	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Gore : Endovascular stents (2017) - Pfizer : Low molecular weight heparin, NOAC (2017) - Bayer : NOAC (2017) - Amgen : PCSK-9 inhibition (2017)
Graham Ian Maklim	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : Advisory Board attendance (2017) - Menarini : Lectures on Prevention and lipid Guidelines only (2017) - Merck Sharp & Dohme : Lectures on Prevention and Pipid Guidelines only (2017)
Grassi Guido	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular (2017) - Medtronic : Cardiovascular (2017) - Menarini : Cardiovascular (2017) - Merck Sharp & Dohme : Cardiovascular (2017)
Halimi Jean-Michel	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Ablynx : caplacizumab (2017) - Alexion : eculizumab (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Halimi Jean-Michel	<ul style="list-style-type: none"> - Servier : hypertension (2017) D - Research funding (departmental or institutional) from healthcare industry. - Novartis : Tuberos Sclerosis Complex (2017)
Haller Hermann	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Kidney (2017) - Boehringer-Ingelheim : Kidney (2017) - Vifor International : Kidney (2017) - Bayer AG : Kidney (2017) - Fresenius Medical Care : Kidney (2017) - Alexion Pharma : Kidney (2017) - MedWiss GmbH : Kidney (2017) - Phenos GmbH : Kidney (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Kidney (2017) - Boehringer-Ingelheim : Kidney (2017) - Vifor Pharma : Kidney (2017)
Heagerty Anthony	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Hypertension (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation (2017) - Biosense Webster : Pacemaker, Ablation (2017) - Biotronik : Pacemaker, catheter (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)
Hobbs Richard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : AF (2017) - Boehringer-Ingelheim : AF, diabetes (2017) - Amgen : Lipids/Anticoag (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : lipids (2017)
lung Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : Anticoagulants (2017) - Novartis : Heart failure drugs (2017) - Edwards Lifesciences : Heart valve prostheses (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Jankowski Piotr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Atrial fibrillation (2017) - Astrazeneca : CAD (2017) - Amgen : Hypercholesterolemia (2017) - SanofiAventis : Hypercholesterolemia (2017) - Servier : Hypertension (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - SanofiAventis : Hypercholesterolemia (2017)
Jelakovic Bojan	Nothing to be declared (2017)
Jennings Catriona Sian	Nothing to be declared (2017)
Juni Peter	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017) - Biosensors International Group : Drug-eluting stents (2017) - The Medicines Company : Thrombin inhibitors (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Karpettas Nikos	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Sanofi Aventis : Irbesartan - Hypertension (2017)
Katus Hugo	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Daiichi Sankyo : Lixiana_NOAK (2017) - Astra Zeneca : Ticagrelor (2017) - Bayer Vital : Xarelto-NOAK (2017) D - Research funding (departmental or institutional) from healthcare industry. - St Jude Medical : Biobank (2017) - Philips : MRT (2017)
Knuuti Juhani	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017) - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)
Kraemer Bernhard	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : NOAC (2017) - Pfizer : NOAC (2017) - Boehringer-Ingelheim : SGLT-2 inhibitor (2017) - Chiesi Pharma : Transplantation (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Kraemer Bernhard	2- Other Positions of Influence 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - President of the German Hypertension Society DHL (2017)
Kroon Abraham	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - CVRx : hypertension, baroreflex activation therapy in resistant hypertension (2017) - Vascular Dynamics : hypertension, MobiusHD carotid stent in resistant hypertension (2017) - Recor Medical : hypertension, renal denervation in resistant hypertension (2017)
Lancellotti Patrizio	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : Ischemic Heart Disease (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : NOAC (2017)
Lazareva Irina	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Actelion, : macitentan, selecsipag (2017)
Leclercq Christophe	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : devices (2017) - Boston Scientific : devices (2017) - Medtronic : devices (2017) - Biotronik : devices (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Leclercq Christophe	<ul style="list-style-type: none"> - Livanova : devices (2017) D - Research funding (departmental or institutional) from healthcare industry. - Biotronik : devices (2017)
Linhart Ales	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension, coronary heart disease, heart failure (2017) - Boehringer-Ingelheim : Aterial fibrillation, diabetes (2017) - Sanofi Aventis : Fabry disease (2017) - Shire HGT : Fabry disease (2017) - Novartis : Heart failure (2017)
Lovic Dragan	Nothing to be declared (2017)
Lurbe Empar	Nothing to be declared (2017)
Manolis Athanasios John	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : atrial fibrillation (2017) - Servier : hypertension (2017) - Berlin Chemie AG : hypertension (2017) - Ferrer Internacional : hypertension (2017) - Recordati International : hypertension (2017) - Menarini : hypertension, heart failure (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Manolis Athanasios John	<p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : AF (2017) - Boehringer-Ingelheim : AF (2017) - Amgen : hyperlipidemia (2017) - Sanofi Aventis : hyperlipidemia (2017)
McDonagh Theresa	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Vifor International : Ferrinject (2017) - Novartis : Honoraria (2017) - Bayer AG : Honoraria (2017)
Mercuro Giuseppe	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Biological treatment in coronary artery disease (2017) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Education (2017)
Messerli Franz	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medscape : Cardiology (2017) - American College of Cardiology : Cardiology (2017) - Pfizer : Hypertension (2017) - Servier : Hypertension (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Messerli Franz	<ul style="list-style-type: none"> - Menarini : Hypertension (2017) - Sandoz : Hypertension (2017) - Hikma : Hypertension (2017) - Medtronics : Hypertension (2017)
Metsarinne Kaj	1- Financial Declaration D - Research funding (departmental or institutional) from healthcare industry. - Novo-Nordisk : semaglutide (2017)
Miglinas Marius	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : hypertension (2017) - Krka Pharma : hypertension (2017)
Muiesan Maria Lorenza	1- Financial Declaration D - Research funding (departmental or institutional) from healthcare industry. - Novartis : sacubritil/valsartan (2017)
Najafov Ruslan	Nothing to be declared (2017)
Nixdorff Uwe	Nothing to be declared (2017)
Noppe Stephanie	1- Financial Declaration D - Research funding (departmental or institutional) from healthcare industry. - LIH(luxembourg institute of health) : Etude ORISCAV (responsable: alaa alkerwi) (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Olsen Michael Hecht	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Management of Hypertension (2017) - Servier : Management of Hypertension (2017) - Boehringer-Ingelheim : SGLT2 inhibitors (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Novo Nordisk Foundation : Research Stipendium (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - I own a small percentage of ATAH which is a small, new start up IT Company producing decision support for Health Care (Cardio.Care). (2017)
Pagava Zurab	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Berlin Chemie AG (Georgia) : Speaker fees (2017) - Servier (Georgia) : Speaker fees (2017) - AstraZeneca (Georgia) : Speaker fees (2017)
Pall Denes	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : cardiovascular / hypertension (2017) - Teva Pharmaceutical Industries : cardiovascular / hypertension (2017) - Berlin Chemie AG : nebivolol / cardiovascular, hypertension (2017) - Egis Pharma : perindopril, indapamid / cardiovascular, hypertension (2017) - Krka Pharma : valsartan, telmisartan / cardiovascular, hypertension (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Pall Denes	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : atrial fibrillation (2017) - Pfizer : diabetes (2017) - Astra Zeneca : diabetes / hypertriglyceridaemia (2017) - Boehringer-Ingelheim : diabetes, heart failure (2017) - Bayer : NOAC / cardiovascular (2017)
Parati Gianfranco	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - OMRON Healthcare : Honoraria for lectures on Blood Pressure Measurement (2017) - Daiichi Sankyo : Honoraria for lectures on Hypertension (2017) - Pfizer : Honoraria for lectures on Hypertension (2017) - Menarini : Honoraria for lectures on Hypertension (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : research on hypertension (2017) - Pfizer : research on hypertension (2017) - Menarini : research on hypertension (2017)
Pavlova Olga	<p>Nothing to be declared (2017)</p>
Pechere-Bertschi Antoinette	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : cardiovascular (2017) - Menarini : cardiovascular (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Pechere-Bertschi Antoinette	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : nephrology (2017)
Perk Joep	Nothing to be declared (2017)
Piepoli Massimo Francesco	Nothing to be declared (2017)
Polonia Jorge Manuel	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Speaker: Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Jaba Recordati, Medinfar, Menarini, Novartis, Sanofi-Aventis, Servier : Antihypertensive drugs and antidiabetic drugs several (2017) - Technimed : antihypertensive drugs (2017)
Ponikowski Piotr	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : anticoagulant, diabetes (2017) - Respicardia : devices (2017) - Novartis : heart failure (2017) - Cardioentis : heart failure (2017) - Berlin Chemie AG : heart failure (2017) - Bayer Healthcare : heart failure (2017) - Vifor Pharma Ltd : heart failure (2017) - CIBIEM : heart failure (2017) - Servier : heart failure, coronary artery disease (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - Amgen : heart failure, lipids (2017) - Pfizer : lipids, heart failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Respicardia : anticoagulant (2017) - BioControl : devices (2017) - Cardionomic : devices (2017) - Impuls Dynamics : devices (2017) - Novartis : heart failure (2017) - Bayer Healthcare : heart failure (2017) - CIBIEM : heart failure (2017) - National Institute of Health : heart failure (2017) - Servier : heart failure, coronary artery disease (2017) - Amgen : heart failure, lipids (2017) - European Union grant : heart failure, prevention (2017)
Porsti Ilkka	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Hyperkalemia (2017) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - Small amount of shares in Orion Pharma Ltd (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Raev Dimitar	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : AF (2017) - Johnson & Johnson : CAD (2017) - Astra Zeneca : CAD, HF (2017) - Pfizer : HF (2017) - Novartis : HF, ACS (2017)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : aortic stenosis (2017) - Menarini : CAD- hypertension (2017) - Novo-Nordisk : diabetes (2017) - Novartis : hypertension (2017) - Unipharma : hypertension-thrombosis (2017) - Abbott : lipids (2017) - Amgen : lipids (2017) - Sanofi Aventis : Lipids (2017) - Lilly : Lipids (2017) - Unilever : lipids (2017) - Merck Sharp & Dohme : lipids (2017) - Vianex : lipids (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Galenica : Lipids (2017) - Teva Pharmaceutical Industries : lipids, hypertension (2017) - Bayer Healthcare : Thrombosis (2017)
Rimoldi Stefano Flavio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Cardiology (2017) - Menarini : Cardiology (2017)
Roffi Marco	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents (2017) - Medtronic : Stents (2017) - Biotronik : stents (2017) - Terumo Inc : stents (2017) - Abbott Vascular : stents (2017)
Romanova Tatiana	<p>Nothing to be declared (2017)</p>
Saade Georges	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : HONORARIA (2017) - Bayer : speaker fees (2017) - Boehringer-Ingelheim : speaker fees (2017) - Novartis : speaker fees (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Saade Georges	<ul style="list-style-type: none"> - Pfizer : speaker fees (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Vifor International : investigator (2017) 2- Other Positions of Influence <ul style="list-style-type: none"> 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - American College of Cardiology (2017)
Sakalyte Gintare	<ul style="list-style-type: none"> 1- Financial Declaration <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Sanofi Aventis : Investigator fee in the clinical trial (2017) D - Research funding (departmental or institutional) from healthcare industry. - European Research Foundation FP7 : Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies (2017) 2- Other Positions of Influence <ul style="list-style-type: none"> 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Lithuanian Health Ministry (2017)
Sattar Naveed	<ul style="list-style-type: none"> 1- Financial Declaration <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : GLP-1 receptor agonist (2017) - Novo-Nordisk : GLP-1 receptor agonist (2017) - Amgen : PCSK9 (2017) - Sanofi Aventis : PCSK9 (2017) - Boehringer-Ingelheim : SGLT2 inhibitor (2017) - Eli Lilly : SGLT2 inhibitor (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Sattar Naveed	<ul style="list-style-type: none"> - Janssen-Cilag : SGLT2 inhibitor (2017) D - Research funding (departmental or institutional) from healthcare industry. - Boehringer-Ingelheim : SGLT2 inhibitor (2017)
Schunkert Heribert	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : N/A (2017) - Astra Zeneca : N/A (2017) - Boehringer-Ingelheim : N/A (2017) - Daiichi Sankyo : N/A (2017) - Novartis : N/A (2017) - Pfizer : N/A (2017) - Servier : N/A (2017) - Sanofi Aventis : N/A (2017) - St. Jude : N/A (2017) - MSD SHARP & DOHME : N/A (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : N/A (2017)
Sdiri Wissem	Nothing to be declared (2017)
Seferovic Petar	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : coronary disease, heart failure (2017)

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Seferovic Petar	<ul style="list-style-type: none"> - Boehringer-Ingelheim : heart failure, hypertension (2017) - Pfizer : heart failure, hypertension (2017) - Berlin Chemie AG : heart failure, hypertension (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Ministry of Science and Education of the Republic of Serbia : heart failure, myocardial and pericardial disease (2017)
Segura Julian	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular (2017) - Medtronic : Cardiovascular (2017) - Pfizer : Cardiovascular (2017) - Menarini : Cardiovascular (2017)
Shaker Amin Fouad	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Brillique Crestor (2017) - Merck Sharp & Dohme : Ingy (2017) - Pfizer : Lipitor Norvasc (2017)
Shechter Michael	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Itamar Medical, Inc. Cesarea, Israel : EndoPat - endothelial function (2017)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<ul style="list-style-type: none"> - Novartis : Arterial Hypertension, Heart Failure (2017) - Merck Sharp & Dohme : Atherosclerosis (2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017) - Pfizer : General Cardiology (2017)
Simpson Iain A	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Siostrzonek Peter	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS (2017) - Lilly : ACS (2017) - Boehringer-Ingelheim : Anticoagulation (2017) - Novartis : heart failure (2017) - Sanofi Aventis : Lipid (2017) - Amgen : Lipid therapy (2017) - Servier : SCA (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes, anticoagulation (2017) - Novartis : heart failure (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Sirenko Yuriy	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Takeda Pharmaceuticals : Asilsartan (2017) - Pfizer : Atorvastatin (2017) - Sanofi Aventis : Ramipril (2017) - Bayer AG : Riociguat (2017) - Servier : Triplexam (2017)
Slavomira Filipova	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : investigator of multicentric international trial (2017) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Servier : investigator of multicentric international trial (2017)
Sokolovic Sekib	<p>Nothing to be declared (2017)</p>
Sousa Uva Miguel	<p>Nothing to be declared (2017)</p>
Stanton Alice	<p>Nothing to be declared (2017)</p>
Stergiou Georgios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulant therapy (2017) - OMRON Healthcare : blood pressure monitors (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Stergiou Georgios	<ul style="list-style-type: none"> - Maisense : Blood pressure monitors (2017) - Microlife : blood pressure monitors (2017) - Novartis : hypertension (2017) - Servier : hypertension (2017) - Sanofi Aventis : hypertension (2017) - Menarini : hypertension (2017) - Vianex : hypertension (2017) - Pharmathen : hypertension (2017) - Galenica. : hypertension (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Microlife : Hypertension (2017) - InBody : Hypertension (2017) - iHealth : Hypertension (2017) - Maisanse : Hypertension (2017)
Thomopoulos Costas	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Hypertension (2017) - St Jude Medical : Hypertension (2017) - Sanofi Aventis : Hypertension (2017) - Menarini : Hypertension (2017) - MSD : Lipids (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Thomopoulos Costas	E - Research funding (personal). - Hellenic Society of Hypertension : Protocol grant (2017)
Trusinskis Karlis	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer : atorvastatin, apixaban (2017) - Boehringer-Ingelheim : dabigatran, empagliflozin (2017) - Servier : ivabradine, perindopril (2017) - Novo-Nordisk : liraglutide (2017) - Berlin Menarini : olmesartan, nebivolol (2017) - Biotronik : orsiro, magmaris (2017) - Sanofi Aventis : ramipril, candesartan (2017) - Bayer : rivaroxabane (2017) - Astra Zeneca : Ticagrelor, dapagliflozin (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Merck Sharp & Dohme : bisoprolol (2017) - Bayer : rivaroxabane (2017)
Tykarski Andrzej	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : Hyperteension (2017) - Berlin Menarini : Hypertension (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
van de Borne Philippe	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes (2017) - Novo-Nordisk : diabetes (2017) - Menarini : hypertension (2017)
Vardas Panagiotis	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - European Society of Cardiology : CONSULTING FEES (2017) - DEAN MEDICUS LTD : CONSULTING FEES (2017) - Bayer : SPEAKER FEES (2017) - Boehringer-Ingelheim : SPEAKER FEES (2017) - MENARINI INTERNATIONAL : SPEAKER FEES (2017) - AFEA S.A. : SPEAKER FEES (2017) - Servier : SPEAKER FEES AND CONSULTING FEES (2017)
Vavlukis Marija	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Jensen, Jensen : investigator (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novo-Nordisk : consultancy (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Viigimaa Margus	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Coagulation (2017) - Novo-Nordisk : Diabetes (2017) - Menarini : Hypertension (2017) - Amgen Inc : Lipids (2017) - Sanofi Aventis : Lipids, hypertension (2017)
Vinereanu Dragos	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Acute Coronary Syndromes, Diabetes (2017) - Boehringer-Ingelheim : Atrial Fibrillation (2017) - Pfizer : Atrial Fibrillation (2017) - Novartis : Cardiovascular prevention, Heart Failure (2017) - Servier : Hypertension, Heart Failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Johnson & Johnson : Clinical trial (2017) - Quintiles : Clinical trial (2017) - PPD Global : Clinical trial (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Johnson & Johnson : Clinical trial (2017) - Quintiles : Clinical trial (2017) - PPD Global : Clinical trial (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Vinereanu Dragos	<ul style="list-style-type: none"> - Dalcor : Clinical trial (2017) 2- Other Positions of Influence <ul style="list-style-type: none"> 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. <ul style="list-style-type: none"> - Vice-rector of the University; President of the Romanian Society of Cardiology. (2017)
Volpe Massimo	<ul style="list-style-type: none"> 1- Financial Declaration <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - Amgen : evolocumab (2017) - Novartis : LCZ696 (2017) - Daiichi Sankyo : olmesartan (2017) - Malesci : olmesartan (2017) - MENARINI INTERNATIONAL : Olmesartan/amlodipine (Hypertension) (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - Merck Sharp & Dohme : sitagliptin (diabetes), losartan (Hypertension, Heart Failure) (2017) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - University "Sapienza" of Rome : Research Award (2017)
Wassmann Sven	<ul style="list-style-type: none"> 1- Financial Declaration <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - Amgen : Cardiovascular (2017) - Astra Zeneca : Cardiovascular (2017) - Boehringer-Ingelheim : Cardiovascular (2017) - Daiichi Sankyo : Cardiovascular (2017) - Novartis : Cardiovascular (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Wassmann Sven	<ul style="list-style-type: none"> - Pfizer : Cardiovascular (2017) - Bristol Myers Squibb : Cardiovascular (2017) - Merck Sharp & Dohme : Cardiovascular (2017) - Volcano : Cardiovascular (2017)
Weber Thomas	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bosch & sons : Blood pressure measurement devices (2017) - Boehringer-Ingelheim : Diabetes (2017) - Novartis : Heart Failure, Hypertension (2017) - Servier : Hypertension (2017) - Menarini : Hypertension (2017) - Jacobi Pharma : Hypertension (2017) - Merck Company : Hypertension (2017) - MSD : Lipidology (2017)
Widimsky Jr Jiri	<p>Nothing to be declared (2017)</p>
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Edwards Lifesciences : invasive Cardiology (2017) D - Research funding (departmental or institutional) from healthcare industry. <ul style="list-style-type: none"> - Abbott : General Cardiology (2017) - Boston Scientific : General Cardiology (2017) - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017) - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) 2- Other Positions of Influence <ul style="list-style-type: none"> 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Wittekoek Janneke	<ul style="list-style-type: none"> 1- Financial Declaration <ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - LEEFH foundation (cascadescreening FH in the Netherlands) : prevention (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. <ul style="list-style-type: none"> - KPN : e-health (2017) - Amgen : prevention (2017) - Philips : prevention (2017) - MSD : prevention (2017)

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : afib (2017) - Pfizer : Afib (2017)
Zelveian Parounak	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Takeda Pharmaceuticals : Hypertension (2017) - Egis Pharma : Hypertension (2017) - Grindex : Hypertension (2017) - Krka Pharma : Hypertension & Atherosclerosis (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2016-2017) - Novartis : Hypertension (2016-2017) - Boehringer-Ingelheim : Oral anticoagulation (2016-2017) - Bayer Healthcare : Oral anticoagulation (2016-2017) - Pfizer/BMS alliance : Oral anticoagulation (2016-2017)
Agewall Stefan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet treatment (2016-2017)
Barbato Emanuele	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Educational courses on FFR (2016) - Boston Scientific : Education courses on rotational atherectomy (2016-2017) - Abbott Vascular : Educational courses on FFR (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Unrestricted grant for an investigator-driven study (2016-2017)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : BVS (2016) - Servier : ivabradine (2016) - Novartis : Serelaxin, ACZ885, AHF Academy (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Pfizer : Apixaban (2016-2017) - Bristol Myers Squibb : Apixaban (2016-2017) - Bayer : Aspirin, rivaroxaban (2016-2017) - MEDSCAPE-the heart.org : Inespecific (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Ferrer Internacional : Trinomia (polypill) (2016-2017) - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2016-2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016) - BMS : CV013-011 - STANDUP-AHF trial (2016-2017) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016-2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016-2017) - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - FAHA (2016) - VP elect. Spanish Society of Cardiology FAHA (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coca Antonio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016) - Merck Serono : Bisoprolol-Amlodipine (2016-2017) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017) - Ferrer Internacional : Torasemide; CardiIncode microchips; Polypill (2016-2017)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - BMS : apixaban (2016) - Sanofi Aventis : CLOPIDOGREL (2016) - Medtronic : corevalve (2016) - Eli Lilly : PRASUGREL (2016) - Astra-Zeneca : ticagrelor (2016) - MSD : VORAPAXAR (2016) - Bayer Healthcare : xarelto (2016) - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : APIXABAN (2016) - Medtronic : COREVALVE (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> - Stago : LABORATORY TEST (2016) - Eli Lilly : PRASUGREL (2016) - FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016) - ICAN : THROMBOSIS (2016) - Astra Zeneca : TICAGRELOR (2016) - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Coman Ioan Mircea	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016-2017) - Johnson & Johnson : antithrombotic (2016-2017) - Bayer AG : antithrombotic (2016-2017) - Sanofi Aventis : dyslipidemia (2016-2017) - Fournier Laboratories : dyslipidemia (2016-2017) - Amgen Inc : dyslipidemia , (2016-2017) - Novartis : HF (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	<ul style="list-style-type: none"> - Vifor International : iron deficiency (2016-2017) - Actelion : PHT (2016-2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016-2017) - Johnson & Johnson : antithrombotic (2016-2017) - Bayer AG : antithrombotic (2016-2017) - Sanofi Aventis : dyslipidemia (2016-2017) - Amgen Inc : dyslipidemia (2016-2017) - Fournier Laboratories : dyslipidemia (2016-2017) - Novartis : HF (2016-2017) - Vifor International : iron deficiency (2016-2017) - Actelion : PHT (2016-2017)
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016) - Biotronik : Pacemaker-Heart Failure (2016) - Edwards Lifesciences : Valvular heart disease (2016) - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Delgado Victoria	<ul style="list-style-type: none"> - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017)
Fitzsimons Donna	Nothing to be declared (2016-2017)
Gaemperli Oliver	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - GE-Healthcare : Imaging (2016) - Amgen Inc : PCSK9 (2016) - Servier : Procorolan (2016) - GE Healthcare : Imaging (2017)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Biotronik : CIEDs and interventional electrophysiology (2016) - Abbott : Pacemaker, Ablation (2017) - Biosense Webster : Pacemaker, Ablation (2017) - Biotronik : Pacemaker, catheter (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Abbott, Biotronik, Medtronic, Boston Scientific : Electropysiology, arrhythmias (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)
lung Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valve Prostheses (2016-2017) - Boehringer Ingelheim : Anticoagulants (2017) - Novartis : Heart failure drugs (2017)
Juni Peter	<p>Nothing to be declared (2016)</p> <p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017) - Biosensors International Group : Drug-eluting stents (2017) - The Medicines Company : Thrombin inhibitors (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Bayer Vital : Xarelto-NOAK (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2016-2017) - Philips : MRT (2016-2017)
Knuuti Juhani	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017) - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Orion : Brain diseases (2016) - AC Immune : Brain diseases (2016) - Antaros : Endocrinology (2016) - Boehringer-Ingelheim : Neurology (2016) - MSD : Neurology (2016) - GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Echo course (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> - Servier : Ischemic Heart Disease (2016-2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic : Structural disease (2016) - Bayer : NOAC (2016-2017)
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sorin Group : devices (2016) - St Jude Medical : devices (2016) - Bayer Healthcare : DOAC (2016) - Boston Scientific : devices (2016-2017) - Medtronic : devices (2016-2017) - Biotronik : devices (2016-2017) - Abbott : devices (2017) - Llvanova : devices (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Biotronik : devices (2017)
McDonagh Theresa	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Vifor International : Ferrinject (2016-2017) - Novartis : Honoraria (2016-2017) - Bayer AG : Honoraria (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Committee member, Speaker fee (2016) - Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016) - Amgen : Metabolic, Lipid (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure Prevention Initiatives (2016)
Ponikowski Piotr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : devices (2016) - BioControl : devices (2016) - Pfizer : lipids (2016) - Boehringer-Ingelheim : anticoagulant, diabetes (2016-2017) - Respicardia : devices (2016-2017) - Novartis : heart failure (2016-2017) - Cardiorentis : heart failure (2016-2017) - Berlin Chemie AG : heart failure (2016-2017) - Bayer Healthcare : heart failure (2016-2017) - Vifor Pharma ltd : heart failure (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - CIBIEM : heart failure (2016-2017) - Servier : heart failure, coronary artery disease (2016-2017) - Amgen : heart failure, lipids (2016-2017) - Pfizer : lipids, heart failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - DC Device : devices (2016) - Cardioentis : heart failure (2016) - Respicardia : anticoagulant (2016-2017) - BioControl : devices (2016-2017) - Novartis : heart failure (2016-2017) - Bayer Healthcare : heart failure (2016-2017) - CIBIEM : heart failure (2016-2017) - Servier : heart failure, coronary artery disease (2016-2017) - Amgen : heart failure, lipids (2016-2017) - Cardionomic : devices (2017) - Impuls Dynamics : devices (2017) - National Institute of Health : heart failure (2017) - European Union grant : heart failure, prevention (2017)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Angelini : Lipids (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Swisspharma : lipids-hypertension (2016) - Astra Zeneca : lipids-thrombosis (2016) - Pfizer : lipids-thrombosis (2016) - Winmedica : lipids-thrombosis (2016) - Boehringer-Ingelheim : thrombosis (2016) - Menarini : CAD- hypertension (2016-2017) - Novartis : hypertension (2016-2017) - Abbott : lipids (2016-2017) - Amgen : lipids (2016-2017) - Sanofi Aventis : Lipids (2016-2017) - Lilly : Lipids (2016-2017) - Unilever : lipids (2016-2017) - Merck Sharp & Dohme : lipids (2016-2017) - Vianex : lipids (2016-2017) - Galenica : Lipids (2016-2017) - Teva Pharmaceutical Industries : lipids, hypertension (2016-2017) - Bayer Healthcare : Thrombosis (2016-2017) - Edwards Lifesciences : aortic stenosis (2017) - Novo-Nordisk : diabetes (2017) - Unipharma : hypertension-thrombosis (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Roffi Marco	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Terumo Inc : coronary catheters (2016) - Johnson & Johnson : coronary catheters (2016) - Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Biotronik : devices (2016) - Terumo Inc : devices (2016) - Abbott Vascular : devices (2016) - Boston Scientific : Stents (2017) - Medtronic : Stents (2017) - Biotronik : stents (2017) - Terumo Inc : stents (2017) - Abbott Vascular : stents (2017)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2016-2017) - Novartis : Arterial Hypertension, Heart Failure (2016-2017) - Merck Sharp & Dohme : Atherosclerosis (2016-2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	- Pfizer : General Cardiology (2016-2017)
Simpson Iain A	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2016-2017)
Sousa Uva Miguel	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Dabigatran (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2016)
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : General Cardiology (2016) - Terumo Inc : General Cardiology (2016) - Bracco Pharmaceutical : General Cardiology (2016) - Boston Scientific : General Cardiology (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Abbott : General Cardiology (2017) - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017) - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Philips : 3D Echocardiography. (2016) - Servier : Clinical case presentation during ESC Cong 2016 (2016) - Pfizer : speaker CV risk factors. (2016) - MSD : speaker. CV risk factors (2016) - Bayer : afib (2017) - Pfizer : Afib (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016) - Abbott : Epidemiology study of Mitral regurgitation (2016)